CML in pregnancy and childhood.

Department of Haematology, Imperial College, Hammersmith Hospital, Ducane Road, London W120NN, UK.
Best practice & research. Clinical haematology (Impact Factor: 2.55). 09/2009; 22(3):455-74. DOI: 10.1016/j.beha.2009.09.008
Source: PubMed

ABSTRACT With the improved survivals offered by the tyrosine kinase inhibitors has come the necessity to address issues relating to quality of life and one such area is that of fertility and parenting. Animal data suggest that imatinib at standard dosages is unlikely to impair fertility in either adult males or females but human data remain limited. Children born to men who are actively taking imatinib at the time of conception appear healthy and current advice is not to discontinue treatment. In contrast the data relating to children born to women exposed to imatinib during pregnancy are less encouraging. Although numbers are small there has been a disturbing cluster of rare congenital malformations such that imatinib cannot be safely recommended, particularly during the period of organogenesis. The appropriate management of children with CML has also been radically changed by the advent of imatinib. The features of the disease at presentation, the natural history and the response to therapy seem to be identical in children to that seen in adults. Now that imatinib has been in clinical use for almost ten years without severe long-term side effects, most physicians are now comfortable advising a trial of imatinib prior to consideration of transplant. Data relating to the efficacy and safety of second generation tyrosine kinase inhibitors in childhood is entirely absent and transplant remains the first choice for patients failing imatinib and perhaps also for young patients with sub-optimal responses.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the past two decades, many improvements have been made in the management of patients with leukemia. Research in this field most often focuses on the youngest and oldest patient age groups. However, the population of patients in between those age groups has received relatively little attention with few studies specifically focusing on them. This important 'age gap' has demonstrated a unique, difficult-to-treat group of patients known as adolescents and young adults, or AYAs. Variably defined in the literature as patients from late teenage years to the age of up to 40 years, the AYA group of patients represents a vulnerable subset of patients now identified to require its own focus, development of therapeutic strategies and parallel emphasis on special support systems involving multidisciplinary psychosocial care. Despite the great advancements that have been realized for patients with chronic myeloid leukemia (CML), the AYA group has seldom been the focus of specific reports and studies, and the outcome appears to lag behind the general population. This review focuses on this subset of AYA patients with CML and summarizes the available data and recent developments, challenges and treatment options for this group of patients. © 2014 S. Karger AG, Basel.
    Acta Haematologica 01/2014; 132(3-4):298-306. DOI:10.1159/000363434 · 0.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasms of the hematopoietic stem cells characterized by a triphasic clinical presentation, and the presence of a reciprocal translocation between chromosomes 9 and 22 or the Philadelphia chromosome (Ph). The juxtaposition of the breakpoint cluster region (BCR) on chromosome 22 with the Abelson gene (ABL) on chromosome 9 leads to a dys-regulation of the ABL intrinsic non receptor tyrosine kinase activity. By controlling downstream pathways involved in cell proliferation, adhesion, and survival, the hybrid oncogene BCR-ABL is considered as a major driver of leukemogenesis in CML. The therapeutic approach for CML has undergone a revolutionary change during the last 2 decades with the Abstract Objective: The introduction of several classes of targeted therapeutics for the treatment of chronic myelogenous leukemia (CML) raises the question of whether male fertility is affected and the degree of this affection, if any, among the different generations of tyrosine kinase inhibitors (TKIs). Additionally, when two drugs are equally effective, the drug with less toxic effect on fertility is favourable. Our aims were to evaluate semen parameters and pituitary gonadal function before and four months after starting TKIs namely, dasatinib, nilotinib, and imatinib in patients with CML. Design: Prospective study. Setting, patients and interventions: We studied the effect of TKIs' first generation (imatinib) and second generation (dasatinib and nilotinib) on semen parameters and endocrine functions in 20 eugonadal male patients with CML, aged between 35 to 51 years. They were receiving imatinib (400 mg) once daily, dasatinib (100 mg) once daily or nilotinib (300 mg) twice daily as upfront therapy. We assessed the serum gonadotropins (LH and FSH) and testosterone (T) secretion and sperm parameters before and after four months of using these TKIs. Results: Four months after starting TKIs, serum testosterone, LH and FSH concentrations decreased significantly. The total sperm count (SC), total and rapid progressive sperm motility, and % sperms with normal morphology decreased significantly versus pre-treatment. After 4 months of therapy, dasatinib had comparatively the least deleterious effects on SC, ejaculate volume (SV), sperm motility and % of sperms with normal morphology (%NM) compared to imatinib and nilotinib. Significant correlations were found between serum T concentrations and semen parameters before and after TKIs therapy including SC (r  0.658 and r  0.73 respectively, p  0.001), rapid progressive motility (r  0.675 and r  0.758, respectively; p  0.001), and the % NM (r  0.752 and r  0.834, respectively; p  0.001). After TKIs therapy, LH were correlated significantly with T concentrations, SV and SC (r  0.434, 0.439 and 0.376, respectively;  p: 0.01). Conclusions: Our study showed that CML patients treated with TKIs have significant decrease of sperm parameters and decreased serum concentrations of serum T, LH and FSH. These potentially toxic effects on spermatogenesis are less prominent in patients treated with dasatinib compared to imatinib and nilotinib. The mechanisms and pathways for these effects need further human and/ or experimental studies. Citation: Yassin MA, Soliman AT, Sanctis VD (2014) Effects of tyrosine kinase inhibitors on spermatogenesis and pituitary gonadal axis in males with chronic myeloid leukemia. J Cancer Res Ther 2:116-121. Copyright:  2014 Yassin MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. Open Access introduction of the tyrosine kinase inhibitors. The use of these agents has changed overall survival as well as the
    08/2014; 2:116-121. DOI:10.14312/2052-4994.2014-18
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic myelogenous leukemia (CML) is a rare disease in children. There is little evidence of biological differences between CML in children and adults, although host factors are different. Children develop distinct morbidities related to the off-target effects of tyrosine kinase inhibitors. The goal of treatment in children should be cure rather than suppression of disease, which can be the treatment goal for many older adults. This article reviews data from the literature on the treatment of CML, discusses the issues that are unique to CML in children, and recommends management that takes these issues into consideration. Copyright © 2015 Elsevier Inc. All rights reserved.
    Pediatric Clinics of North America 02/2015; 62(1):107-119. DOI:10.1016/j.pcl.2014.09.008 · 2.20 Impact Factor